LMLN and leishmaniasis: Two T-cell epitope peptides derived from gp63, one of the main surface glycoproteins of L. major, provided significant protection to CBA mice against severe cutaneous lesions.29 Many studies on Leishmania antigen-derived peptide vaccines are described in literature; for a review, see De Brito et al.30 But most studies that describe effective protection against leishmaniasis provided by a peptide vaccine were performed in experimental mouse models.